JUMPCAN(SH:600566)2016-04-24 16:00Financial Performance - The company's operating performance in Q1 2016 showed steady growth, with operating revenue reaching CNY 1,156,619,952, an increase of 27.88% compared to the same period last year[8]. - Net profit attributable to shareholders was CNY 209,124,158, reflecting a year-on-year increase of 31.01%[8]. - The company reported a basic earnings per share of CNY 0.268, which is a 31.37% increase from CNY 0.204 in the same period last year[8]. - Total operating revenue for Q1 2016 reached CNY 1,156,619,952, an increase of 28% compared to CNY 904,464,742 in the same period last year[31]. - Net profit for Q1 2016 was CNY 208,742,032, representing a 31.7% increase from CNY 158,500,990 in Q1 2015[31]. - The total comprehensive income attributable to the parent company was CNY 209,124,157.72, compared to CNY 159,628,820.20 in the previous period, reflecting an increase of approximately 31%[32]. - The basic and diluted earnings per share were both CNY 0.268, up from CNY 0.204 in the previous year, representing a growth of about 31.4%[35]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 280,833,860, up 60.64% from the previous year[8]. - Cash generated from operating activities increased by 60.64% to 280,833,860.20, attributed to larger sales scale and increased cash recovery[17]. - Cash flow from operating activities generated a net inflow of CNY 280,833,860.20, compared to CNY 174,820,736.83 in the previous period, marking an increase of approximately 60.5%[36]. - The total cash and cash equivalents at the end of the period amounted to CNY 469,996,979.06, a decrease from CNY 530,950,463.79 at the end of the previous period[37]. - The company reported a net decrease in cash and cash equivalents of 100.29 thousand RMB during the quarter[40]. - Cash and cash equivalents increased by 73.78% to CNY 469,996,979, attributed to expanded sales and improved collection of receivables[14]. - Cash used in investing activities improved by 67.83% to -81,266,765.62, mainly due to last period's payment for acquiring Dongke Pharmaceutical equity[17]. - The total cash outflow from investing activities was CNY 81,269,165.62, down from CNY 536,143,911.62 in the previous period, showing a significant reduction in investment expenditures[36]. - The net cash flow from financing activities was CNY -31,434.04, compared to CNY -41,511,988.90 in the previous year, indicating a slight improvement in financing activities[37]. Assets and Liabilities - Total assets increased by 9.81% to CNY 3,937,107,097 compared to the end of the previous year[8]. - As of March 31, 2016, the total assets of Hubei Jichuan Pharmaceutical Co., Ltd. amounted to CNY 3,937,107,096.90, an increase from CNY 3,585,422,094.86 at the beginning of the year[26]. - The total liabilities increased to CNY 1,015,534,837.89 from CNY 872,591,868.03, reflecting a growth of 16.4%[27]. - The company's total equity reached CNY 6,697,415,468.62, a marginal decrease from CNY 6,698,326,854.13[30]. - The company’s retained earnings rose to CNY 1,343,795,751.04, up from CNY 1,134,671,593.32, reflecting a growth of 18.4%[27]. - The company’s total current liabilities increased to CNY 984,194,833.17 from CNY 840,263,936.79, an increase of 17.1%[27]. Shareholder and Corporate Governance - The company had a total of 12,346 shareholders at the end of the reporting period[12]. - The company received approval for a non-public offering of up to 31,654,016 new shares, although the issuance has not yet been implemented[18]. - The company committed to ensuring asset independence and integrity post-major asset restructuring, with the controlling shareholder being Jichuan Holdings[19]. - Jichuan Holdings and its controlled companies will not engage in similar business activities to avoid competition with the listed company[19]. - The company will prioritize any business opportunities that may compete with the listed company to ensure compliance with commitments[20]. - The company is focused on maintaining operational independence and avoiding conflicts of interest post-restructuring[20]. - Hubei Jichuan Pharmaceutical has pledged to avoid any related party transactions unless strictly necessary and compliant with regulations[22]. - The company is focused on maintaining a complete and independent internal management structure to ensure operational independence[22]. - The financial department operates independently, ensuring accurate financial decision-making and reporting[22]. - Hubei Jichuan Pharmaceutical has committed to compensating for any losses incurred due to violations of independence commitments[22]. Other Financial Metrics - Cash and cash equivalents decreased to CNY 72,181.55 from CNY 172,472.11, indicating a decline of 58%[29]. - Accounts receivable increased to CNY 1,218,195,398.62 from CNY 1,099,194,584.80, indicating a rise of about 10.8%[26]. - Inventory decreased to CNY 133,861,866.26 from CNY 170,649,368.32, reflecting a decline of approximately 21.6%[26]. - Non-current assets totaled CNY 1,921,399,648.46, compared to CNY 1,867,650,381.58 at the beginning of the year, marking an increase of about 2.9%[26]. - Financial expenses decreased by 78.46% to -1,018,745.63 due to no bank loan interest expenses and increased deposit interest[16]. - Investment income dropped by 100% to 0.00, primarily due to the expiration of previously idle fundraising financial products[16].